Overview

A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Status:
RECRUITING
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Phase:
PHASE1
Details
Lead Sponsor:
Eli Lilly and Company